Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death

Cancer

Volumn 109, Issue 10, 2007, Pages 2142-2153

  Uwagawa, Tadashi ^a,c   Li, Zhongkui ^a   Chang, Zhe ^a,b   Xia, Qianghua ^a,b   Peng, Bailu ^a   Sclabas, Guido M ^a,d   Ishiyama, Satoshi ^a   Hung, Mien Chie ^a,b   Evans, Douglas B ^a   Abbruzzese, James L ^a   Chiao, Paul J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Cancer League of Bern ^*  (Switzerland)

Author keywords

(TNF ); Apoptosis; Nuclear factor B (NF B); PEA3; Receptor; Synthetic serine protease inhibitor FUT 175; Tumor necrosis factor

Indexed keywords

CASPASE 8; DNA FRAGMENT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; NAFAMSTAT MESILATE; PROTEIN BID; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PEA3; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CHROMATIN IMMUNOPRECIPITATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TIME; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CELL LINE, TUMOR; ENZYME ACTIVATION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GUANIDINES; HUMANS; I-KAPPA B PROTEINS; NF-KAPPA B; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SERINE PROTEINASE INHIBITORS; TRANSCRIPTION FACTORS;

EID: 34248376363     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22658     Document Type: Article

References (25)

1. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol. 2002;2:725-734.
2. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18:2195-2224.
3. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell. 2002;109(Suppl):S81-96.
4. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000; 18:621-663.
5. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181-190.
6. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-310.
7. Arlt A, Vorndamm J, Muerkoster S, et al. Autocrine production of interleukin 1β confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 2002;62:910-916.
8. Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1α in induction of constitutive NF-κB activation in pancreatic cancer cells. J Biol Chem. 2004;279:16452-16462.
9. Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene. 2003;22:1365-1370.
10. Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K. NF-κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 2004;108:181-188.
11. Issekutz AC, Roland DM, Patrick RA. The effect of FUT-175 (Nafamstat Mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo. Int J Immunopharmacol. 1990;12:1-9.
12. Gabryelewicz A, Prokopowicz J, Bodzenta A, Bielecki W, Rydzewska G. Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis. Digestion. 1988;40:19-24.
13. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661:342-345.
14. Iwaki M, Oda M, Ozeki M, et al. [Pharmacological studies of FUT-175, nafamstat mesilate. III. Anti-inflammatory activities of FUT-175]. Nippon Yakurigaku Zasshi. 1984;84:373-384.
15. Tajima H, Ohta T, Elnemr A, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA. Int J Cancer. 2001;94:699-704.
16. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
17. Sclabas GM, Fujioka S, Schmidt C, Evans DB, Chiao PJ. NF-κB in pancreatic cancer. Int J Gastrointest Cancer. 2003;33:15-26.
18. Frazier ML, Fernandez E, de Llorens R, et al. Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. Int J Pancreatol. 1996;19:31-38.
19. Fujioka S, Schmidt C, Sclabas GM, et al. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-κB. J Biol Chem. 2004;279:27549-27559.
20. Schmidt C, Peng B, Li Z, et al. Mechanisms of proinflammatory cytokine-induced biphasic NF-κB activation. Mol Cell. 2003;12:1287-1300.
21. Noguchi S, Nakatsuka M, Konishi H, Kamada Y, Chekir C, Kudo T. Nafamostat mesilate suppresses NF-κB activation and NO overproduction in LPS-treated macrophages. Int J Immunopharmacol. 2003;3:1335-1344.
22. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119-127.
23. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFα-induced apoptosis. Cell. 2003;115:61-70.
24. Kemper O, Wallach D. Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor. Gene. 1993;134:209-216.
25. Tando Y, Algul H, Schneider G, et al. Induction of IkappaB-kinase by cholecystokinin is mediated by trypsinogen activation in rat pancreatic lobules. Digestion. 2002;66:237-245.